NCT06370351View on ClinicalTrials.gov

A Phase I/II Clinical Trial with SENS-501 in Children Suffering from Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 21, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2031

Conditions
OTOF Gene MutationDFNB9Congenital DeafnessHearing DisordersEar DiseasesOtorhinolaryngologic DiseasesDeafnessHearing Loss, Sensorineural
Interventions
COMBINATION_PRODUCT

SENS-501 administration

Administration of SENS-501 with a dedicated administration system

Trial Locations (2)

75015

RECRUITING

Hopital Necker Enfants Malades, Paris

NSW 2145

RECRUITING

Childrens Hospital Westmead, Westmead

Sponsors

Lead Sponsor

Sensorion
All Listed Sponsors
lead

Sensorion

INDUSTRY

NCT06370351 - A Phase I/II Clinical Trial with SENS-501 in Children Suffering from Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations | Biotech Hunter | Biotech Hunter